Evidence map›Paper›PMID 38319477›Full record

Observational studyJournal of clinical immunology2024

High Prevalence of Long COVID in Common Variable Immunodeficiency: An Italian Multicentric Study.

Annalisa Villa, Cinzia Milito, Carla Maria Deiana, Renato Finco Gambier, Alessandra Punziano, Helena Buso, Patrick Bez, Gianluca Lagnese, Giulia Garzi, Giulia Costanzo and 7 more

Open access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Journal of clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Annalisa Villa *Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.
Cinzia Milito *Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.
Carla Maria DeianaDepartment of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.
Renato Finco GambierRare Diseases Referral Center, Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Department of Medicine - DIMED, University of Padova, Treviso, Italy.
Alessandra PunzianoDepartment of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
Helena BusoRare Diseases Referral Center, Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Department of Medicine - DIMED, University of Padova, Treviso, Italy.
Patrick BezRare Diseases Referral Center, Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Department of Medicine - DIMED, University of Padova, Treviso, Italy.
Gianluca LagneseDepartment of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
Giulia GarziDepartment of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.
Giulia CostanzoDepartment of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.
Gloria GiannuzziDepartment of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.
Chiara PagnozziRare Diseases Referral Center, Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Department of Medicine - DIMED, University of Padova, Treviso, Italy.
Virgil A S H DalmDepartment of Internal Medicine, Division of Allergy & Clinical Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Giuseppe SpadaroDepartment of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
Marcello RattazziRare Diseases Referral Center, Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Department of Medicine - DIMED, University of Padova, Treviso, Italy.
Francesco Cinetto *Rare Diseases Referral Center, Internal Medicine I, Ca' Foncello Hospital, AULSS2 Marca Trevigiana, Department of Medicine - DIMED, University of Padova, Treviso, Italy. francesco.cinetto@unipd.it.ORCID 0000-0001-8486-5850
Davide Firinu *Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy.
Ca' Foncello Hospital · ITSapienza University of Rome · ITUniversity of Cagliari · ITUniversity of Naples Federico II · ITErasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The long-term effects of SARS-CoV-2 infection represent a relevant global health problem. Long COVID (LC) is defined as a complex of signs and symptoms developed during or after SARS-CoV-2 infection and lasting > 12 weeks. In common variable immunodeficiency (CVID) patients, we previously reported higher risk of hospitalization and death during SARS-CoV-2 infection, as well as prolonged swab positivity and frequent reinfections. The aim of the present study was to assess the risk of LC in an Italian cohort of CVID patients. We used a translated version of the survey proposed by Centers for Disease Control and Prevention (CDC) to collect data on LC. In the enrolled cohort of 175 CVID patients, we found a high prevalence of LC (65.7%). The most frequent LC symptoms were fatigue (75.7%), arthralgia/myalgia (48.7%), and dyspnea (41.7%). The majority of patients (60%) experienced prolonged symptoms, for at least 6 months after infection. In a multivariate analysis, the presence of complicated phenotype (OR 2.44, 95% CI 1.88-5.03; p = 0.015), obesity (OR 11.17, 95% CI 1.37-90.95; p = 0.024), and female sex (OR 2.06, 95% CI 1.09-3.89; p = 0.024) significantly correlated with the development of LC. In conclusion, in this multicenter observational cohort study, we demonstrated that CVID patients present an increased prevalence of LC when compared to the general population. Improved awareness on the risk of LC in CVID patients could optimize management of this new and alarming complication of SARS-CoV-2 infection.

Indexed as

Common Variable ImmunodeficiencyCOVID-19FemaleHumansItalyPost-Acute COVID-19 SyndromePrevalenceSARS-CoV-2United Stateschronic lung diseasecommon variable immunodeficiencycomplicated phenotypeCOVID-19Long COVIDobesitySARS-CoV-2

Identifiers

PMID38319477
PMCPMC10847195
OpenAlexW4391566721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.